A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH (1989) N Engl J Med 320: 545-50 Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Graham NM, Zeger SL, Park LP, Phair JP, Detels R, Vermund SH, Ho M, Saah AJ (1991) Lancet 338: 265-9 Effect of treating co-infections on HIV-1 viral load: a systematic review. Modjarrad K, Vermund SH (2010) Lancet Infect Dis 10: 455-63 CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D (2002) J Exp Med 195: 869-79 Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH (2017) Sci Transl Med 9: Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Spritzler J, Mildvan D, Russo A, Asthana D, Livnat D, Schock B, Kagan J, Landay A, Haas DW, Adult AIDS Clinical Trials Group (2003) Clin Infect Dis 37: 551-8 Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP, Adult AIDS Clinical Trials Group Study (2006) Clin Infect Dis 42: 401-7 Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Haas DW (2006) Clin Infect Dis 42: 1197-9 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD (2007) Int J Epidemiol 36: 294-301 Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration (2014) Int J Epidemiol 43: 691-702 Increasing rate of pneumonia hospitalizations in the Bronx: a sentinel indicator for human immunodeficiency virus. Drucker E, Webber MP, McMaster P, Vermund SH (1989) Int J Epidemiol 18: 926-33 Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Haas DW, Stone J, Clough LA, Johnson B, Spearman P, Harris VL, Nicotera J, Johnson RH, Raffanti S, Zhong L, Bergqwist P, Chamberlin S, Hoagland V, Ju WD (2000) Clin Pharmacol Ther 68: 367-74 Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR (2013) AIDS 27: 1321-9 Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) AIDS 18: 2391-400 Transitioning HIV care and treatment programs in southern Africa to full local management. Vermund SH, Sidat M, Weil LF, Tique JA, Moon TD, Ciampa PJ (2012) AIDS 26: 1303-10 On 'the natural history of HIV and AIDS in women'. Kelley KF, Vermund SH (1992) AIDS 6: 1406-8 HIV/AIDS and its risk factors in Pakistan. Khawaja ZA, Gibney L, Ahmed AJ, Vermund SH (1997) AIDS 11: 843-8 Pharmacogenomics and HIV therapeutics. Haas DW (2005) J Infect Dis 191: 1397-400 Millions of life-years saved with potent antiretroviral drugs in the United States: a celebration, with challenges. Vermund SH (2006) J Infect Dis 194: 1-5 Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. Bacellar H, Muñoz A, Hoover DR, Phair JP, Besley DR, Kingsley LA, Vermund SH (1994) J Infect Dis 170: 1284-7 Impaired hepatic protein synthesis in AIDS patients with low vitamin A levels. Haas DW, Raffanti S, Chytil F, Lakey D, Alls S (1995) J Infect Dis 172: 1167-9 Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB (2002) J Infect Dis 185: 428-38 CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. Stein DS, Korvick JA, Vermund SH (1992) J Infect Dis 165: 352-63 Gastrointestinal cryptococcosis. Washington K, Gottfried MR, Wilson ML (1991) Mod Pathol 4: 707-11 Integrating cervical cancer prevention in HIV/AIDS treatment and care programmes. Mwanahamuntu MH, Sahasrabuddhe VV, Stringer JS, Parham GP (2008) Bull World Health Organ 86: D-E The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA (2012) Cancer 118: 6226-33 Needle injuries among pediatric housestaff physicians in New York City. Melzer SM, Vermund SH, Shelov SP (1989) Pediatrics 84: 211-4 Pediatric acquired immunodeficiency syndrome with negative human immunodeficiency virus antibody response by enzyme-linked immunosorbent assay and Western blot. Goetz DW, Hall SE, Harbison RW, Reid MJ (1988) Pediatrics 81: 356-9 Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. Motsinger A, Azimzadeh A, Stanic AK, Johnson RP, Van Kaer L, Joyce S, Unutmaz D (2003) J Virol 77: 8153-8 Human cryptosporidiosis. Crawford FG, Vermund SH (1988) Crit Rev Microbiol 16: 113-59 Linear cutaneous lesions of Kaposi's sarcoma: a clinical clue to the diagnosis of acquired immunodeficiency syndrome. Rendon MI, Roberts LJ, Tharp MD (1988) Arch Dermatol 124: 327-9 Estimating population prevalence of human immunodeficiency virus infection in urban areas with high rates of intravenous drug use: a model of the Bronx in 1988. Drucker E, Vermund SH (1989) Am J Epidemiol 130: 133-42 Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Muñoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, Saah AJ, Kingsley LA, Seminara D, Phair JP (1993) Am J Epidemiol 137: 423-38 Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study. Vermund SH (2001) Am J Epidemiol 153: 628-31 Tuberculosis and acquired immunodeficiency syndrome: a historical perspective on recent developments. Haas DW, Des Prez RM (1994) Am J Med 96: 439-50 Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA (2003) J Acquir Immune Defic Syndr 34: 475-81 Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T, ACTG 384 and DACS 250 Study Teams (2011) J Acquir Immune Defic Syndr 58: 363-70 Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, Nicotera F, Rebeiro P, Erdem H, Rueff M, Haas DW (2003) J Acquir Immune Defic Syndr 34: 119-26 Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J (2004) J Acquir Immune Defic Syndr 35: 138-43 Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Fingleton B, Matrisian LM (2001) Curr Opin Oncol 13: 368-73
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.